Fhlki7ivqwcyevis8vni immunovia

Immunovia AB

Lund, SE

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden.

Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases earlier and more accurately than previously possible.

Decades of clinical immunoproteomics research resulted in the development of IMMray™, our core technology platform based on antibody microarray analysis.

IMMray™ is dedicated to the early diagnosis of cancer, to predicting disease progression and to monitoring the therapeutic responsiveness of cancers. The platform technology can also be used for biomarker discovery through Immunovia’s discovery tool for proteome scanning IMMray™ PS (Proteome Survey). Immunovia’s technology is designed not only for cancer but also for... Show more »

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden.

Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases earlier and more accurately than previously possible.

Decades of clinical immunoproteomics research resulted in the development of IMMray™, our core technology platform based on antibody microarray analysis.

IMMray™ is dedicated to the early diagnosis of cancer, to predicting disease progression and to monitoring the therapeutic responsiveness of cancers. The platform technology can also be used for biomarker discovery through Immunovia’s discovery tool for proteome scanning IMMray™ PS (Proteome Survey). Immunovia’s technology is designed not only for cancer but also for autoimmune diseases. It is superior to conventional proteomic technologies that suffer from low throughput and impaired resolution and sensitivity.

The first test based on Immunovia’s platform, IMMray™ PanCan-d, is now under commercialization with several clinical evidence studies in the planning phase and also ongoing. IMMray™ PanCan-d is the only blood-based test available for early detection of pancreatic cancer in stage I and stage II when the cancer is still resectable. Diagnosing patients in stage I and stage II could increase the overall 5-year survival rate from 3-4% to approx. 59%1.

Immunovia’s solution combines a single-chain fragment variable (scFv) antibody library in an array-based set-up, antibody biomarker signatures and an advanced, in-house developed clinical algorithm and software for interpreting the data. The company has its own antibody library, antibody production and purification as well as its own chip/array production. Our clinical laboratory services are now undergoing validation for ISO accreditation.

Selected Publications

  • Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer Carl A. K. Borrebaeck. Nature Reviews Cancer (2017) doi:10.1038/nrc.2016.153. Published online 03 February 2017
  • Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics Payam Delfani, Linda Dexlin Mellby, Malin Nordström, Andreas Holmér, Mattias Ohlsson, Carl A. K. Borrebaeck, Christer Wingren. PLOS ONE. July 2016.
  • Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis Anna Sandström Gerdtsson, Christer Wingren, Helena Persson, Payam Delfani, Malin Nordström, He Ren, Xin Wen, Ulrika Ringdahl, Carl A.K. Borrebaeck, Jihui Hao. Molecular Oncology, 2016
« Show less

Immunovia AB has not listed any services.

Ask A Question Find what you're looking for? If not, you can ask this lab a question:
Antibody Microarray
Price on request

Antibody microarray full system solution - including reference laboratory read-outs (from in-house antibody development - scFV - through microarray developments, microarray scanning, biomarker quantification, establishment of predictive biomarker profiles based on in-house developed biostatistics/software and cohort read-outs).

Antibody microarray full system solution - including reference laboratory read-outs (from in-house antibody development - scFV - through microarray developments, microarray scanning, biomarker quantification, establishment of predictive biomarker profiles based on in-house developed biostatistics/software and cohort read-outs).

« Show less
Bioinformatics
Price on request

Immunovia applies front-edge bioinformatic workflows and tools for analyzing microarray data, including data handling, normalization, biomarker signature identification and classification. The microarray data generated is used to build Immunovia’s own predictive model based on biomarker signatures and the support vector machine... Show more »

Immunovia applies front-edge bioinformatic workflows and tools for analyzing microarray data, including data handling, normalization, biomarker signature identification and classification. The microarray data generated is used to build Immunovia’s own predictive model based on biomarker signatures and the support vector machine (SVM) classification algorithm.

Biomarker signatures able to accurately classify/distinguish a disease state are identified through a stepwise biomarker/analyte selection process. One biomarker is excluded at a time in an iteration process adopting Immunovia’s in-house developed backward elimination approach. The backward elimination algorithm, based on SVM classification, generates the combination of biomarkers showing the highest classification power between healthy and disease states.

« Show less
Recombinant antibody production
Price on request

As part of the production unit, Immunovia’s in-house recombinant antibody production and purification platform provides high quality antibodies for microarray fabrication.

Recombinant antibodies are produced and purified in-house using robotic systems and high-throughput processes.

The source of renewable recombinant... Show more »

As part of the production unit, Immunovia’s in-house recombinant antibody production and purification platform provides high quality antibodies for microarray fabrication.

Recombinant antibodies are produced and purified in-house using robotic systems and high-throughput processes.

The source of renewable recombinant antibodies is crucial when to produce antibody-based microarray tests. Therefore, we use a specially designed library of recombinant antibodies, specifically designed at the molecular level, to ensure the availability of antibodies with optimal function of the chip.

« Show less
Omics
Price on request
Request a quote for more information about this service.
Protein Arrays
Price on request
Request a quote for more information about this service.
Computational Modeling
Price on request
Request a quote for more information about this service.
Protein Services
Price on request
Request a quote for more information about this service.
Biology
Price on request
Request a quote for more information about this service.
Biostatistics & Bioinformatics
Price on request
Request a quote for more information about this service.
Proteomics
Price on request
Request a quote for more information about this service.
Therapeutic Monoclonal Antibody (mAb) Development
Price on request
Request a quote for more information about this service.
Antibody Services
Price on request
Request a quote for more information about this service.
Biochemistry & Molecular Biology
Price on request
Request a quote for more information about this service.

Immunovia AB has not received any ratings.

Be the first to endorse Immunovia AB

Endorse this lab